Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Mahshid |
||
| Line 26: | Line 26: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Hematology]] | |||
[[Category:Immunology]] | |||
Revision as of 22:11, 26 November 2017
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma laboratory tests On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Laboratory tests of diffuse large B cell lymphoma include complete blood count, blood chemistry studies, flow cytometry, immunohistochemistry, cytology, genetic testing, and immunophenotyping.
Laboratory Tests
Laboratory tests of diffuse large B cell lymphoma include:[1][1]
- Complete blood count (CBC)
- Blood chemistry studies
- Flow cytometry
- Immunohistochemistry
- Cytology (for primary CNS lymphoma only)
- Genetic testing
- Immunophenotyping BCL-2+, BCL6+/-, CD10+, CD15+, CD20+, CD22+, CD30+, CD79a+, EBNA-2+, Fox-P1+, IRF4/MUM1+, LMP-1+, Surface 4 or cytoplasmic immunoglobulin (Ig) is absent
References
- ↑ 1.0 1.1 National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov